CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Net product sales	$ 858,245	$ 784,182
Sanofi collaboration revenue	210,367	219,694
Bayer Collaboration Revenue	193,939	179,592
Other revenue	56,440	17,381
Total revenues	1,318,991	1,200,849
Expenses:
Research and development	507,435	470,112
Selling, general, and administrative	296,846	289,677
Cost of goods sold	61,253	78,942
Cost of collaboration and contract manufacturing	22,915	32,810
Total expenses	888,449	871,541
Income from operations	430,542	329,308
Other income (expense):
Other income (expense), net	9,248	3,483
Interest expense	(7,501)	(2,640)
Total other income (expense)	1,747	843
Income before income taxes	432,289	330,151
Income tax expense	(183,358)	(148,766)
Net income	$ 248,931	$ 181,385
Net income per share - basic	$ 2.36	$ 1.74
Net income per share - diluted	$ 2.16	$ 1.59
Weighted average shares outstanding - basic	105,572	104,290
Weighted average shares outstanding - diluted	115,106	114,228
Statements of Comprehensive Income
Net income	$ 248,931	$ 181,385
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax	6,956	(4,208)
Comprehensive income	$ 255,887	$ 177,177